Medicalization of Death

Definition

The "medicalization of death" refers to the post-1960 shift in which medical care — rather than public health infrastructure or nutrition — became the primary mechanism driving mortality decline in the United States. The term captures a qualitative transition in how reductions in death rates are achieved: from one-time infrastructure investments (clean water, sanitation, food safety) to ongoing, expensive healthcare delivery concentrated in the elderly.

Key Ideas

Era 1 (1900–40): Public health and nutrition dominated. Infant and child mortality fell sharply; improvements required sanitation infrastructure and dietary sufficiency, not individual clinical care. Cutler and Miller (2005) estimate that water purification alone accounts for approximately 50% of the reduction in US urban mortality in the first third of the 20th century.
Era 2 (1940–60): Antibiotics (sulfa drugs, penicillin) extended the public-health-like model to infections — a single class of drugs treated many previously lethal diseases with modest ongoing delivery burden.
Era 3 (1960–90): Cardiovascular disease (CVD) treatment — statins, antihypertensives, coronary care units, coronary artery bypass grafting — generated approximately 98% of mortality reductions in Cutler and Meara's analysis, and approximately 70% of the 7-year US life expectancy gain from 1960–2000 in the Cutler, Deaton, and Lleras-Muney (2006) synthesis (with roughly two-thirds of the CVD gain from medical advances and one-third from smoking reduction). This required sustained clinical relationships, expensive hardware, and specialist care. Mortality improvements were now inseparable from healthcare expenditure.
Behavioral vs. medical attribution: Smoking cessation contributed to the CVD decline, but the timing argument (CVD mortality decline preceded mass behavioral change) and the pattern of age-specific improvement support medical care as the primary driver (Cutler and Meara 2001; Cutler, Deaton, and Lleras-Muney 2006).

How It Works

The mechanism is the shift in which age group's mortality is driving aggregate improvements:

Pre-1960: young-age mortality drove gains (infants, children, young adults). Improvements came from reducing infection burden — achievable through population-level public health measures.
Post-1960: elderly mortality drove gains. Cardiovascular events and cancer occur disproportionately at old ages. Preventing death at these ages requires ongoing pharmacological management and acute intervention — inherently clinical, not infrastructural.

The implication: the marginal cost of an additional life-year of improvement rose dramatically post-1960, because elderly clinical care is expensive in ways that chlorinating water supplies is not.

Why It Matters

Healthcare spending: The medicalization of death is a key structural explanation for why US healthcare spending grew rapidly from the 1960s onward. The elderly became the primary beneficiaries of mortality-reducing innovation, and Medicare (enacted 1965) created the financing mechanism.
Lee-Carter $b_x$ tilt: The shift from young-age to old-age mortality dominance produced the empirical $b_x$ tilt in mortality forecasting models — as elderly $b_x$ weights grew, each unit of improvement generated more $e_0$ gain. See Lee-Carter Model and Period Mortality.
DI beneficiary mortality: Disability Insurance (DI) beneficiaries have access to Medicare after a 24-month waiting period. Their mortality trajectories are sensitive to CVD treatment availability, making the medicalization era directly relevant to understanding long-run improvement in DI cohort survival. See DI Beneficiary Mortality.
Policy implications: If future mortality improvement depends primarily on continued medical investment in the elderly (as this framework implies), then scenarios projecting "natural" mortality improvement independent of healthcare spending are implausible.

Open Questions

Attribution uncertainty: The relative contribution of medical care vs. behavioral change (especially smoking) to the post-1960 CVD decline remains debated. The timing argument is suggestive but not definitive.
Post-1990 era: The Cutler/Meara framework ends at 1990. The subsequent period introduced both treatment advances (revascularization, statins) and new mortality threats (opioid epidemic, obesity). Whether a "fourth era" has emerged — defined by a reversal in mortality improvement concentrated in working-age adults — is an active area of inquiry. See Deaths of Despair.
Global applicability: The medicalization of death may be a US-specific phenomenon amplified by Medicare's financing structure. Countries with different health system designs show different cost trajectories for equivalent mortality gains.